Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics, Inc. (ANIK)
:ANIK
ANIK Stock Chart & Stats
$9.75
$0.27(1.72%)
At close: 4:00 PM EST
$9.75
$0.27(1.72%)
Day’s Range― - ―
52-Week Range$7.87 - $18.37
Previous CloseN/A
Volume22.29K
Average Volume (3M)119.83K
Market Cap
$137.29M
Enterprise Value$102.06M
Total Cash (Recent Filing)$57.99M
Total Debt (Recent Filing)$24.51M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Mar 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding14,421,219
10 Day Avg. Volume180,387
30 Day Avg. Volume119,834
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.57
Price to Sales (P/S)2.02
P/FCF Ratio-103.95
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.52
Enterprise Value/Ebitda5.04
Forecast
1Y Price Target
$16.00Price Target Upside64.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$111.29M
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company ended the quarter with $58.0 million in cash and equivalents and no debt, demonstrating strong financial health.
Investment RatingAnalyst maintains an OUTPERFORM investment rating on Anika shares and increases the price target to $16 from $15.
Share RepurchaseAnika Therapeutics plans a $15 million share repurchase, reflecting confidence in the company's valuation.
Bears Say
Execution IssuesAnika has not executed on some of its key objectives in recent years and, in our view, has not optimized its communications with investors regarding the inherent value we believe we see in the business.
Profitability ChallengesAnika's adjusted EBITDA fell short of expectations, indicating challenges in profitability.
Revenue DeclineAnika's OEM channel revenue declined by 19.8%, impacting overall sales performance.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics, Inc.’s price range in the past 12 months?
Anika Therapeutics, Inc. lowest stock price was $7.87 and its highest was $18.37 in the past 12 months.
What is Anika Therapeutics, Inc.’s market cap?
Anika Therapeutics, Inc.’s market cap is $137.29M.
When is Anika Therapeutics, Inc.’s upcoming earnings report date?
Anika Therapeutics, Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 109 days.
How were Anika Therapeutics, Inc.’s earnings last quarter?
Anika Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.22.
Is Anika Therapeutics, Inc. overvalued?
According to Wall Street analysts Anika Therapeutics, Inc.’s price is currently Undervalued.
Does Anika Therapeutics, Inc. pay dividends?
Anika Therapeutics, Inc. does not currently pay dividends.
What is Anika Therapeutics, Inc.’s EPS estimate?
Anika Therapeutics, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Anika Therapeutics, Inc. have?
Anika Therapeutics, Inc. has 14,421,219 shares outstanding.
What happened to Anika Therapeutics, Inc.’s price movement after its last earnings report?
Anika Therapeutics, Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went up 2.285%.
Which hedge fund is a major shareholder of Anika Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANIK
Anika Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (64.10% Upside)
$16.00 (64.10% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.13%
12-Months-Change
Fundamentals
Return on Equity
-8.73%
Trailing 12-Months
Asset Growth
-18.14%
Trailing 12-Months
Company Description
Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (ANIK) is a biopharmaceutical company focused on developing and commercializing innovative products for the orthopedic market. The company specializes in the development of therapies for pain management and tissue regeneration, particularly in the areas of osteoarthritis and joint preservation. Anika's core products include viscosupplements, which are hyaluronic acid-based injections used to alleviate joint pain, as well as regenerative medicine solutions aimed at improving healing and function in musculoskeletal conditions.
ANIK Company Deck
ANIK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in the Commercial Channel, significant progress in regulatory submissions, and improved cost management. However, these positives were offset by revenue declines in key segments and challenges with pricing pressure and study results.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$16.00
▲(64.10% Upside)
Technical Analysis
Ownership Overview
4.25% Insiders
12.03% Mutual Funds
28.79% Other Institutional Investors
43.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---